The construction of a single pharmacophore model for the identification of potential triple inhibitors for the treatment of patients with AD consists of an innovative approach, in view of the unavailability of such models for AChE, BuChE, and BACE-1 described in the literature. This evidence concerns the gene BACE1 and Alzheimer disease.